Susceptibility of human immunodeficiency virus type 1 replication in vitro to acyclic adenosine analogs and synergy of the analogs with 3'-azido-3'-deoxythymidine.

Antimicrobial Agents and Chemotherapy
M S SmithJ S Pagano

Abstract

The replication of human immunodeficiency virus in vitro is inhibited by some acyclic adenosine derivatives, such as 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)-2,6-diaminopurine [(S)-HPMPDAP], as well as by 3'-azido-3'-deoxythymidine (AZT). In a human T-lymphocyte cell line, C3, at 6 days postinfection, the 50% effective concentration (EC50) of AZT was 0.02 microM and the 90% effective concentration (EC90) was 0.33 microM; for PMEA, the EC50 was 1.9 microM and the EC90 was 27 microM. For (S)-HPMPDAP, the EC50 was 2.3 microM and the EC90 was 36 microM. Most combinations of AZT and PMEA produced a synergistic effect. In the T-cell line C3, the combination indices for 50 to 90% inhibition of virus replication ranged from 0.25 to 1.25. Combinations of PMEA (or other members of this group) with AZT appear to be worth further study for the possible treatment of acquired immunodeficiency syndrome.

References

Sep 1, 1987·Antimicrobial Agents and Chemotherapy·J C LinJ S Pagano
Dec 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·M G DavisE S Huang
Jan 7, 1988·Nature·R A FisherR T Schooley
Mar 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·S KenneyJ Pagano
Jul 1, 1988·Antimicrobial Agents and Chemotherapy·R PauwelsE De Clercq
Jun 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·P C ZamecnikP S Sarin
May 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·D C Montefiori, W M Mitchell
Nov 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·M MatsukuraS Broder
Oct 2, 1986·Nature·E De ClercqP C Maudgal

❮ Previous
Next ❯

Citations

Aug 1, 1991·Journal of Virological Methods·N K AyisiL F Qualtiere
Aug 1, 1996·Trends in Microbiology·D E Hassett, J L Whitton
Nov 14, 1997·General Pharmacology·M Witvrouw, E De Clercq
Mar 3, 1998·Trends in Microbiology·A M KriegH L Davis
Feb 1, 1994·Journal of Medical Primatology·C C TsaiR Benveniste
Jan 1, 1991·Antimicrobial Agents and Chemotherapy·M S SmithJ S Pagano
Nov 26, 2013·Pharmaceutical Research·Denisa DiblíkováKateřina Vávrová
Nov 26, 2005·Uirusu·Wataru Sugiura
Sep 14, 1990·Biochemical and Biophysical Research Communications·I C BathurstP J Barr
Jun 1, 1992·AIDS Research and Human Retroviruses·R F SchinaziP M Feorino
Apr 22, 2009·AIDS·Brij B SaxenaSidney Lerner
Apr 1, 1995·Clinical Microbiology Reviews·E De Clercq

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.